In this respect, approaches aimed at reducing nuclear MATR3 (through nucleus-specific antisense oligonucleotides, ASOs) or promoting the translocation of nuclear MATR3 to the cytoplasm (through small molecules) could be developed into a novel ALS treatment, reinforcing the translational potential of our findings. The gene discussed is MATR3; the disease is amyotrophic lateral sclerosis.